The guideline provides guidance on definitive local therapy options for non-small cell lung cancer with limited extracranial metastases. It emphasizes the need for a patient-centered, multidisciplinary approach to treatment decisions.
A recent study published in JAMA Oncology reveals that disparities in cancer care are linked to differences between clinicians' and patients' identities. Younger, lower-income minorities were disproportionately affected by delayed care due to these identity differences.
The ACC Cardio-oncology Course aims to equip clinicians with the latest strategies and best practices for managing cardiovascular health in cancer patients. The course will feature joint presentations of oncologists and cardiologists, showcasing real-life patient care and collaboration across teams.
An international panel of experts has developed standardized definitions for immunotherapy side effects, providing a shared vocabulary for clinicians to standardize clinical practice guidelines. This will help support clinicians in offering the best treatment to patients and enable research into biomarkers predicting adverse effects.
A new study published in JNCCN identifies a targeted approach to improve end-of-life conversations for people with cancer. Researchers found that specially trained oncology infusion room nurses can increase the rate of advance care planning, leading to more supported decision-making.
The NRG Oncology combined trial results indicate that pathologic complete response (pCR) is associated with improved survival outcomes for patients with localized soft tissue sarcoma. pCR can be used as a prognostic factor for clinical outcomes in future STS research, with patients achieving higher overall and disease-free survival rates.
Adding pembrolizumab to chemotherapy greatly improves patient outcomes in both MMR-deficient and proficient tumors. Progression-free survival increases by 70% in MMR-deficient tumors and 46% in MMR-proficient tumors.
Researchers identified ARID1A and PIK3CA as potential targets for drug development in recurrent and metastatic cervical cancer. The study found that these mutations were associated with improved survival rates, suggesting their potential as new treatment options.
A co-location model for cancer diagnostic services at a community health center in Boston reduced time to diagnosis from 32 days to 12 days. The program, which has been in operation for 12 years, was designed to bring oncology diagnostics and patient navigation services into the community health center.
The NCCN Annual Conference will debut a new hybrid format featuring in-person events at a new venue, allowing for hallway conversations and networking opportunities. The conference will also showcase more than 100 abstract poster presentations on various oncology-related categories.
A recent study found that immunotherapy costs accounted for 84% of the net increase in Medicare spending on outpatient cancer care at the end of life. Payments for radiation oncology decreased by 2%, while palliative care spending rose, reflecting a shift towards hypofractionated radiation treatments.
Patients with resectable NSCLC treated with neoadjuvant nivolumab show improved five-year recurrence-free and overall survival rates compared to historical outcomes. Major pathological responses after neoadjuvant nivolumab may be associated with lower risk of disease recurrence and death.
The study validated the clinical utility of Strata Oncology's proprietary pan-solid tumor predictive biomarker, Immunotherapy Response Score (IRS), which predicts response to checkpoint inhibitor therapy. IRS captures tumor biology and microenvironment by combining tumor mutation burden with quantitative expression of PD-L1, PD-1, ADAM...
Researchers analyzed over 500,000 patient records and found that patients diagnosed at age 70 were nearly twice as likely to be passed over for post-surgical radiation therapy. This significant gap in treatment recommendations suggests that cognitive heuristics play a major role in physician decision-making.
Researchers analyzed tumor microenvironment of pancreatic cancer, revealing two major defects that inhibit immune response. The study suggests a new approach using anti-CD137 agonist antibody treatment in combination with anti-PD-1 immunotherapy to activate T cells.
The EMBRACE-I study demonstrated the superiority of personalized brachytherapy in treating locally advanced cervical cancer. A targeted approach using magnetic resonance imaging-defined tumor volume resulted in a high tumor control rate and low risk of recurrence.
Researchers have made a breakthrough in precision oncology for patients with metastatic urothelial carcinoma, identifying that certain cell surface molecules decrease or are absent in these patients, making them resistant to the new drug enfortumab vedotin.
Researchers at the Princess Máxima Center found that concentrating surgery for children with neuroblastoma resulted in shorter operation times and reduced blood loss. The study also showed a decrease in side effects, although further research is needed to confirm improved survival rates.
A nationwide retrospective study showed that adjuvant chemotherapy after neo-adjuvant chemotherapy and surgery significantly improved overall survival in patients with pancreatic adenocarcinoma, regardless of lymph node status or resection margins. The study included nearly 900 patients and was published in JAMA Oncology.
The updated guideline provides recommendations on the use of radiation therapy and systemic therapy after surgery to treat patients with endometrial cancer. It considers the role of surgical staging and molecular profiling techniques in determining whether a patient should receive post-operative therapy.
The Máxima Butterfly program offers 28 PhD positions in pediatric oncology, focusing on international collaboration and multidisciplinary exchange. Researchers will receive training from leading experts and gain access to innovative techniques and insights.
The ESMO Immuno-Oncology Congress 2022 will present results from over 240 studies worldwide, exploring new insights on immune checkpoint inhibitors, biomarkers for treatment response, and combination therapy efficacy. The congress aims to accelerate progress in immuno-oncology.
The Princess Máxima Center has been awarded a Marie Sklodowska-Curie COFUND grant to train 28 PhD students from around the world in pediatric oncology research. The program aims to advance the field and promote international collaboration.
A new report by the European Groundshot Commission highlights current and future challenges in cancer research across Europe. The authors estimate that approximately one million cancer diagnoses were missed during the COVID-19 pandemic, and the war in Ukraine poses a significant threat to clinical trials and workforce gaps.
Patients with non-metastatic soft tissue sarcoma can safely receive hypofractionated treatment over three weeks instead of five, achieving similar tumor control and no increased risk of wound complications. The study found comparable rates of major wound complications between the two treatment courses.
Adding stereotactic body radiation therapy (SBRT) to sorafenib significantly improves overall survival, progression-free survival, and time to tumor progression in patients with advanced hepatocellular carcinoma. SBRT was shown to be effective without increasing toxicity.
A large-scale analysis of VA medical centers found that facilities with lower yearly PSA screening rates had higher rates of metastatic prostate cancer in subsequent years. The study supports the benefits of prostate cancer screening in reducing metastatic prostate cancer risk, particularly for high-risk groups like Black patients.
Researchers developed an AI model that uses daily step counts to predict the likelihood of unplanned hospitalization during cancer therapy, offering personalized care and potential prevention of treatment interruptions. The model was tested on data from wearable consumer devices and showed strong predictive performance.
The NRG-HN004 trial found that radiotherapy with durvalumab did not improve progression-free survival or overall survival compared to cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma who have a contraindication to cisplatin. The study highlighted the need for further research in this population.
A randomized phase III trial shows that adding radiation therapy to systemic therapy can delay tumor progression and lengthen survival without compromising quality of life. The combination of SBRT and sorafenib appears more effective than the drug on its own.
In a first-in-human trial, FLASH radiation treatment was found safe and effective for pain relief in patients with bone metastases. The study showed significant pain relief in 7 out of 10 patients, with minimal side effects.
A recent study supports fourth vaccination for cancer patients to protect them against COVID-19. Patients with solid tumours and hematological cancers showed a significant increase in antibody levels after a fourth dose of one of the currently approved vaccines.
The new SIO-ASCO guideline recommends the use of acupuncture, massage therapy, and other integrative therapies for managing breast cancer-related joint pain, general cancer pain, and chemotherapy-induced peripheral neuropathy. The guidelines also acknowledge areas that need further research to support their recommendations.
Late-breaking results at ESMO Congress 2022 reveal a strong association between air pollution and non-small cell lung cancer, with exposure to particulate matter linked to increased risk. The research underscores the need for environmental sustainability in oncology, particularly in cancer prevention and early detection.
A recent clinical trial at UT Southwestern Medical Center successfully tested stereotactic ablative radiation therapy (SAbR) for patients with oligometastatic kidney cancer. The study found that more than 90% of patients with disease control at one year without systemic therapy, and no serious side effects were experienced.
A new scale called the Geriatric Oncology-Potentially Inappropriate Medications (GO-PIMs) Scale was found to be more effective at predicting frailty than conventional methods. The scale identifies high-risk medications linked to falls and fatigue, allowing oncology teams to deprescribe them and improve patients' overall health.
A new set of guidelines aims to increase patient diversity in lung cancer clinical trials by relaxing eligibility requirements. The recommendations, published in JAMA Oncology, suggest that patients with prior or concurrent cancers, brain metastases, and mild liver impairment can be included in trials.
A multi-national study found that over half of clinical trials leading to FDA-approved anticancer medicines are not available for independent scrutiny. The lack of transparency hinders the use of data for further research into the safety and efficacy of medicines.
A recent study published in Blood Advances found a significant disparity in the representation of women among medical educators, with women comprising just 37.7% of speakers at hematology and medical oncology board review lectures. The study also highlights the importance of increasing diversity in educational opportunities to promote ...
A quality improvement project at Dartmouth Cancer Center increased serious illness conversations between patients and providers from 0% to 70%, reflecting the importance of early discussions on prognosis and treatment options. The project's success was attributed to standardized work, an engaged interdisciplinary team, and system-level...
A study published in the Journal of Clinical Oncology found that biochemical failure is not a reliable surrogate endpoint for overall survival in patients with recurrent prostate cancer. The researchers recommend considering metastasis-free survival (MFS) as the best surrogate endpoint for overall survival in this population.
A new drug combination of ramucirumab and pembrolizumab significantly extended overall survival in advanced non-small cell lung cancer patients who had progressed on prior immunotherapy. The study found a 31% reduction in risk of death compared to standard therapy, with median overall survival times of 14.5 months.
St. Jude researchers will present novel treatments for pediatric brain tumors, including a response rate of 86.8% for high-risk neuroblastoma patients. The hospital will also share findings on disparities in survival rates and improve childhood cancer outcomes worldwide through the World Health Organization Global Initiative.
The Society for Integrative Oncology has partnered with the Journal of Integrative and Complementary Medicine (JICM) to advance evidence-based integrative healthcare. This partnership benefits SIO members by offering discounted Open Access publishing fees, while also providing worldwide exposure for research in integrative oncology.
A nationwide study of 100 million hospitalizations found that percutaneous coronary intervention is safe and increasing among cancer patients. The study suggests that PCI can nearly double from 2016 to 2018 among patients with thrombocytopenia, without significantly increasing mortality.
A study of over 4,800 medical oncology practices found that Black patients had higher rates of chemotherapy-related emergency department visits and hospitalizations compared to white patients. The researchers developed reliable measures to assess these inequities, with potential for identifying high- and low-equity practices.
The NCCN Annual Conference focuses on the cancer patient journey, featuring state-of-the-art practice algorithms, updates to clinical guidelines, and new therapies. Leading experts present treatment recommendations for various cancer types, including breast, colorectal, and lung cancer.
Researchers found that adding atezolizumab to chemoradiation treatment was safe and demonstrated immune activation in women with node-positive, locally advanced cervical cancer. The study also showed increased peripheral blood T-cell receptor clonal expansion and tumor-associated T-cell clones.
The study found that homologous recombination repair mutant type (HRRmt) was prognostic of progression-free survival and predictive for olaparib activity in women with recurrent platinum-sensitive ovarian cancer. Patients with BRCA mutations showed clinically significant activity when treated with experimental drugs.
Researchers found that adjuvant radiation therapy compared to early salvage therapy reduced mortality risk in men with pN1 prostate cancer. The study, published in the Journal of Clinical Oncology, showed a 8% decrease in mortality for each additional positive pelvic lymph node found at surgery.
A comprehensive review of over 60 studies confirms that COVID vaccination is around 80% effective in protecting people with cancer against SARS-CoV-2 infection. The mRNA vaccines were found to be the most effective, and multiple vaccinations are recommended for better protection.
Researchers at Moffitt Cancer Center have developed patient-derived cells that can be used to study leptomeningeal disease, a rare complication of cancer. The cells provide a new opportunity for scientists to understand the disease and identify potential therapeutics.
A new study by the Princess Máxima Center for Pediatric Oncology has found that one third of children with a Wilms' tumor, the most common form of childhood kidney cancer, have a hereditary predisposition. This discovery has led to the implementation of extensive genetic testing for all children with this disease in the Netherlands.
A study by researchers at the University of Illinois found that oncology dietitians rarely ask cancer patients about food insecurity, despite awareness that many experience it. The dietitians' estimates of prevalence varied widely, and most did not use validated tools to screen for food insecurity.
A new dietary tool can quickly and accurately assess micronutrient levels in oncology patients, helping to find better nutritional solutions for cancer treatment. Tested on 112 patients, the 21-item food frequency questionnaire can identify suboptimal micronutrient intakes in just 10 minutes.
The ACC cardiooncology course is designed to educate clinicians on improving awareness, identification, monitoring, and management of cardiovascular diseases in cancer patients. The course aims to help clinicians minimize cardiotoxicity from cancer therapies, leading to improved overall survival and quality of life for oncology patients.
A new study from Regenstrief Institute identifies divergent priorities among cancer patients and their caregivers during active treatment, with patients focusing on physical issues like pain and caregivers prioritizing social support. The research emphasizes the need for enhanced whole-family approaches to supportive oncology care deli...
A single genetic test using RNA sequencing has been used for all children with cancer in the Netherlands since 2018, improving diagnosis and treatment in seven cases. The technique picked up 78 fusion genes, 23 of which led to a more accurate diagnosis or possible treatment.
The NRG-RTOG 1010 clinical trial found that adding trastuzumab to chemoradiation and surgery did not improve disease-free survival for HER2-positive esophageal adenocarcinoma patients. Despite this, the study highlights future research opportunities to explore combining trastuzumab with other HER2-targeting agents.
A new meta-analysis of randomized clinical trials found that adding androgen deprivation therapy (ADT) to definitive radiotherapy prevents one cancer from metastasizing for every 10 to 15 men treated. Prolonging adjuvant ADT also showed significant benefits, while neoadjuvant ADT was not effective beyond two months.